

April 2021 CTSC newsletter

HSC-CTSC <HSC-CTSC@salud.unm.edu>

Thu 4/1/2021 11:32 AM



Clinical & Translational Science Center Newsletter

April 2021

Letter from the Director



Dear Colleagues,

April promises to be a busy month for the CTSC. We hope you and yours are safe, healthy, and productive as we advance our research efforts.

In our featured stories this month we have some exciting research trials which are directly impacting public health. Our PCI group is supporting a pilot study investigating alternative treatments for Adolescent Idiopathic Scoliosis (AIS). AIS is the most common type of scoliosis in children between 10 and eighteen years old. Led by Dr. Selina Silva, the study evaluates the use of joint manipulation, trigger point, and myofascial release in treating AIS. Dr. Silva's study will help inform the use of less-invasive methods in a field where typical treatment involves bracing or surgery.

The recently completed Search study, led by Dr. Kathryn Fietze and Amanda Collar, MD/PhD candidate, investigated the risk of Chlamydia trachomatis (Ct) transmission associated with sex toy use by women. Their study's findings will inform future research into how medical practitioners can best advise and counsel women on safe sex toy use and hygiene. This will contribute towards the reduction of Ct transmission, which is the most common sexually transmitted bacterial infection worldwide.

Last in our featured stories, researchers and clinicians alike will find interest in attending the Southwest Clinical Trial Network's Community Advisory Group meeting on June 16, where Dr. Larry Leeman will present about the buprenorphine microdosing protocol currently in the pilot stage. This protocol may help prevent pregnant patients from having to go through opioid withdrawal.

We also have updated information on COVID-19 funding opportunities. We encourage you to look for the weekly memos for current information and funding opportunities.

We encourage everyone to sign up for the COVID-19 vaccine: <https://cvaccine.nmhealth.org/>. The CDC advises good COVID-safety habits, including social distancing and masking, for those who have received the vaccine.

All standard CTSC services are available at this time. We encourage PIs to reach out to our Research Concierge (HSC-CTSCResearchConcierge@salud.unm.edu) with questions and/or to setup a consultation with the CTSC team.

We endeavor to update each section of the CTSC newsletter monthly. Every part of the CTSC is integral to our purpose and funding. Each PI has a personal, professional investment in the information we provide. Please submit that information to our team. The CTSC is here for your support.

The committed faculty, staff, and students at CTSC continue their research projects and look for innovative ways to support our communities. If you are interested in a rigorous quantitative rural research project focused on COVID-19, please contact me (RLarson@salud.unm.edu) to start a dialogue.

The Health Sciences Center Office of Research website contains information on specific research-related updates (including the Research Continuity Guidelines for both [Laboratories & Research Facilities](#) and [Clinical Trial Research Faculty & Staff](#)) and can be accessed through the following link: <https://hsc.unm.edu/research/>.

Should you have any questions about our assets and services, please contact the CTSC Research Concierge at HSC-CTSCResearchConcierge@salud.unm.edu. If you have any issues finding the information that you need, please reach out to [the CTSC Newsletter Team](#) and they will get back to you.

As always, thank you so much for your continued support of the Clinical & Translational Science Center!

Warm regards,

Richard S. Larson, MD, PhD

PI, CEO and Director, Clinical & Translational Science Center

CTSC Leadership

CTSC Director, CEO & Principal Investigator: Richard S. Larson, MD, PhD

Associate Director, CTSC: Matthew Campen, PhD

Associate Director, CTSC: Nancy Pandhi, MD, PhD, MPH

Chief Administrative Officer: Carla Cordova, MPH

Administrative Component Director: Beth Tigges, PhD, RN, PNP, BC

Tracking & Evaluation Module Lead: Beth Tigges, PhD, RN, PNP, BC

Quality & Efficiency Module Lead: Beth Tigges, PhD, RN, PNP, BC

Informatics Component Director: Christophe Lambert, PhD

Community & Collaboration Component Director: Mark Unruh, MD

Community Engagement Module Lead: Nancy Pandhi, MD, PhD, MPH

Collaboration and Commercialization Module Lead: Eric Prossnitz, PhD

Translational Endeavors (TE) Component Director: Christopher Abbott, MD

Translational Workforce Development (TWD) Module Lead: Karlett Parra, PhD

Pilot Translational & Clinical Studies (PTC) Module Lead: Corey Ford, MD, PhD

Research Methods (RM) Component Director: Mark Unruh, MD

Biostatistics, Epidemiology & Research Design (BERD) Module Lead: Mark Unruh, MD

Regulatory Knowledge & Support (RKS) Module Lead: Corey Ford, MD, PhD

Hub Research Capacity (HRC) Component Director: Nancy Pandhi, MD, PhD, MPH

Integration of Special Populations (ISP) Module Lead: Nancy Pandhi, MD, PhD, MPH

Participant Clinical Interactions (PCI) Director: Christopher Abbott, MD

Network Capacity (NC) Component Director: Hengameh Raissy, PharmD

Trial Innovation Network (TIN) Module Lead: Hengameh Raissy, PharmD

Drug Discovery & Repurposing Core Lead: Hakim Djaballah, PhD

Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD) Module Lead: Kimberly Page, PhD, MPH

KL2 Mentored Career Development Component Director: Matt Campen, PhD

Clinical Laboratory Medical Director: Qian-Yun Zhang, MD, PhD

Featured Stories

PCI Supporting Pilot Study on Myofascial and Articular Treatment of Adolescent Idiopathic Scoliosis



Dr. Selina Silva, Associate Professor in the Division of Pediatric Orthopedics, is currently conducting a clinical trial entitled, Myofascial and Articular Treatment of Adolescent Idiopathic Scoliosis. This CTSC pilot study investigates the treatment of Adolescents Idiopathic Scoliosis (AIS) using Dynamic Myofascial and Articular Mobilization and Reorganization (DMAMAR). According to the Scoliosis Research Society, AIS is the most common type of scoliosis affecting children between 10 and 18 years old.

In the past 25 years there has been significant findings related to the understanding of scoliosis and the genetics and biochemistry correlated with this condition. However, there have not been advances to the standard treatment of scoliosis, which involves bracing and/or surgery. The protocol in this study will implement individualized exercise and the use of myofascial and articular treatment with an aim of reducing the rate of progression of scoliosis and degree of curvature. The active treatment group will receive treatment which includes joint manipulation to the thoracic and lumbar spine and pelvis, and mobilization of the cervical spine as indicated. Muscle trigger point and myofascial and fascial release will also be used. The procedures are gentle techniques performed by the Co-Investigator, Dr. Lucy Whyte-Ferguson, D.C., to release tight muscles and fascia. In addition, treatment participants receive heel lists

and/or arch supports as indicated, along with exercise equipment such as a doorway chin-up bar and a small ball for rib mobilization. This approach to the treatment of scoliosis will be evaluated to determine if it is effective in controlling the progression of spinal curvature and rib prominence in adolescent with Idiopathic Scoliosis.

The PCI coordinators are supporting Drs. Silva and Whyte Ferguson with this study, and the CTSC clinic facilities are utilized for study visits. This study has the potential of having a direct impact of our community by providing an alternative means of treatment for AIS.

SEARCH Project Contributes to Understanding of Sex Enrichment Aid Safety



Dr. Kathryn Fietze and Amanda Collar, MD/PhD candidate, successfully completed a CTSC pilot study investigating the potential risk associated with sexual enrichment aid (SEA i.e. sex toys like vibrators and dildos) use in *Chlamydia trachomatis* (Ct) transmission. Ct infection is the most common sexually transmitted bacterial infection worldwide, and a potential source of Ct reinfection is thought to be from a new or untreated partner. Additionally,

little is known about SEA behaviors among women, including prevalence and frequency of use, common cleaning behaviors, and sharing behaviors. The study hypothesized that could be a source for Ct reinfection or transmission. Through creating a cross-sectional REDCap survey, the study recruited 800 sexually active women between the ages of 18-35 years old via social media, and from that pool, 24 were selected for qualitative interviews. Women were separated by self-reported sexual orientation into three groups: Women who have Sex with Men (WSM), Women who have Sex with Women & Men (WSWM), and Women who have Sex with Women (WSW).

Results showed that the majority of all women, regardless of sexual orientation, endorse SEA use, with statistical analysis showing SEA use was 1.55 times greater among WSWM compared to WSM. Furthermore, many women engage in potentially risky behavior including inconsistent SEA cleaning and sharing SEAs without condoms. It is common for women to share SEAs with partners, but the majority of women are not counseled on safe SEA use and hygiene by medical practitioners. When women are counseled on SEA use, the information received varies widely between sexual orientation groups. WSW, in particular, may be under-counseled on these issues. Despite having statistically higher risk of sharing SEAs, no WSW reported being counseled on this topic.

"I feel like that would be a really great addition to the conversation about sexual activity and safety practices. I feel like that is definitely missing from any sort of sexual healthcare kind of conversation...I've gone out of my way to educate myself. It really would have been nice if it was just part of the conversation with whoever is talking to me about birth control and condoms, if they also were able to include something about safe sex toy use."

• Participant 18

The majority of women interviewed would feel comfortable being counseled by a medical practitioner on safe sex toy use and hygiene. Women's comfort being counseled on sex toy use depended on a number of factors. The "qualities" of the medical practitioner was discussed most often, with many stating they prefer nonjudgmental, open, professional, and friendly providers. Many women also preferred female practitioners.

Additionally, the pilot study surveyed medical practitioners to understand counseling behaviors. The majority of medical practitioners do not counsel women on safe sex toy use. Additionally, most providers are not aware of professional guidelines and have not been trained on counseling patients on safe sex toy use. Yet, many practitioners do feel comfortable and qualified to do so.

Save the Date: Southwest Clinical Trials Network Presentation on Buprenorphine Microdosing on June 16, 2021



The CTSC OPIOIDD function is happy to announce the upcoming quarterly Southwest Clinical Trials Network's Community Advisory Group Meeting, on Thursday June 16th 2021 from 12:00-1:00pm. Special Focus of the CAG: Dr. Larry Leeman will present about the exciting new Buprenorphine Microdosing protocol currently being piloted in the UNM Milagro Clinic. A buprenorphine microdosing protocol carries the benefits of avoiding the need for pregnant patients to enter withdrawal, and occurring outpatient regardless of gestational age. A Q&A session will follow the presentation.

All are welcome to attend this important meeting. To register, please visit:

<https://hsc-unm.zoom.us/meeting/register/tJckf-moqT4rH9x-Kw0-dE6hga26f46jd7HH>

For more information, please contact Dr. Page at pagek@salud.unm.edu.

Menu of Services & Resources

- [Biostatistics Support](#)
- [Brain & Behavioral Disorders](#)
- [Citing the Clinical & Translational Science Center](#)
- [Clinical Trials Participant Clinical Interactions](#)
- [Community Engagement](#)
- [Community Health Network](#)
- [Database Mining](#)
- [Drug Repurposing](#)
- [KL2 Scholars](#)
- [Intramural Funding](#)
- [Laboratory Services](#)
- [Pilot Funding](#)
- [Trial Innovation Network](#)
- [Quality & Efficiency](#)

- [Regulatory Knowledge & Support](#)
- [Rural Health Research](#)
- [Team Science & Commercialization](#)
- [Training](#)
- [Vulnerable Populations](#)

Administration

Tracking & Evaluation (T&E)

The Tracking and Evaluation Team is piloting a new "Common Metric" called the Median Accrual Metric. This metric is intended to look at our CTSC's ability to recruit and retain research participants. This metric will look at the entire calendar year for 2020 and will be reported in August of 2021.

Quality & Efficiency (Q&E)

The Quality and Efficiency Team continues to work on two specific process improvements initiatives. These two projects will conclude in June of 2021 and will be evaluated for how the projects impacted our CTSC.

Informatics

Data Requests & "Using Data Courses"

The CTSC's Informatics core has helped hundreds of clinical researchers leverage UNMH's electronic health records and other medical databases to find eligible subjects for clinical trials, evaluate medical practice trends, and conduct longitudinal research projects upon nationwide cohorts. If you are interested in finding out more about how to use big data in your research please read the descriptions of our "Using Data Courses" <https://hsc.unm.edu/ctsc/training/training-catalog.html> , you may also register on this same webpage to attend the course. If you are interested in an overview for your staff or faculty zoom meeting please contact mvalencia-reed@salud.unm.edu to arrange for a presentation.

Informatics also supports REDCap, if you have any questions about REDCap, please contact the REDCap Support Team at ctscredcap@salud.unm.edu.

Community & Collaboration (C&C)

Community Engagement & Research Core (CERC)

DIPeX Training May 12-14, 2021

The Health Experiences Research Network is offering a virtual training from May 12th to May 14th, 2021 via Zoom. All attendees will be trained on the implementation of the Database of Individual Patients' Experiences (DIPeX) methodology, topic selection, recruitment, qualitative interviewing, and online module development.

The price of this training is \$180 for students and residents and \$380 for all others. If you are a faculty or staff member at the University of New Mexico then there is an option for using tuition remission as well. [Please register here](#). More information will be sent over the coming months regarding a brief, mandatory asynchronous training course and meeting.

If you have any questions about the training please contact Jeff Carter at jeacarter@salud.unm.edu for more information. Thank you!

Team Science & Commercialization

CTSC promotes several events a year to promote Team Science and Commercialization- including both Hackathon and BioVenture. Promoting collaboration across academic disciplines, scientists are able to bring together ideas and fill in gaps to help move research out of the lab and into the market.

These events bring together clinicians, engineers, entrepreneurs, programmers, scientists, and students to form teams that worked to develop healthcare innovations and design a pitch allowed participants to practice skills necessary to begin the process of commercialization, a vital step to ensure technologies can reach patients.

As we start to plan for the upcoming BioVenture, we ask that you take a quick survey and let us know your thoughts: <https://ctsctrials.health.unm.edu/redcap/surveys/?s=LK8R89TYDE>.

For additional information and to register for upcoming Synergy meetings, please visit the webpage: <https://hsc.unm.edu/research/ctsc/programs/team-science.html>.

Find out more about ASCEND Hub resources and activities on the ASCEND Hub website: <https://ascendhub.org/>.

Translational Endeavors (TE)i

Translational Workforce Development (TWD)

Write to Excite NIH Grant Reviewers

The NIAID recently released a short article, "[Writing a Winning Application—Write To Excite](#)" that described some great ways to engage your reviewers' interest. If you were intrigued by this article and want to learn more about how to build excitement in grants, sign up for the CTSC's [course on NIH grantsmanship](#). This Zoom session is appropriate for anyone looking for ways to improve their NIH grant strategy.

For more information, contact Regis Lacher at rlacher@salud.unm.edu.

Course Offerings and Consultations – Free of Cost

Translational Workforce Development has numerous [course offerings](#) and can even provide consultations as requested to assist you in your goals! Please request a [consultation](#) or additional information on any courses offered. The TWD team may be reached via HSC-CTSCTWDTraining@salud.unm.edu.

For information regarding TWD, please visit our webpage: <https://hsc.unm.edu/research/ctsc/training/index.html>.

Pilot Awards

The UNM CTSC provides a variety of Pilot Award Programs that distribute intramural funding for clinical and translational research at the Health Sciences Center, including two rounds of funding for our standard RFAs annually. To access a Funding Calendar of CTSC opportunities, please use this link: <https://hsc.unm.edu/research/ctsc/pilot-funding/funding-calendars/index.html>.

Please visit our web site at <https://hsc.unm.edu/research/ctsc/pilot-funding/index.html> for additional information.

Research Methods (RM)

Biostatistics, Epidemiology, and Research Design (BERD)

Dr. Laura Nervi Developing Health Literacy App with CTSC Team

According to the Centers for Disease Control, over a third of adults in the U.S. have low health literacy. Low health literacy prevents people from making appropriate health decisions, and is especially prevalent in minority populations, the medically underserved, the elderly, and those with a low socioeconomic status. Dr. Laura Nervi is working with the CTSC App team to develop a smartphone app which will address this gap in Spanish speakers. Her pilot project seeks to deliver a science-based health literacy and English as a Second Language (ESL) program for Spanish-speakers through an interactive language and health smartphone application. The content is based on the Health Literacy and English as a Second Language Curriculum previously developed by a team led by Dr. Francisco Coto Mas.

The program will include chronic disease prevention and disease management content. While it is a prototype, the objective is to obtain more funding to make the application more robust (and ready to be tested by the community partners and future users). The first phase is fully functional for pilot testing. The pilot project has developed an Android-compatible application, and the team has plans to develop an iOS version as well. The new language/health learning program will significantly increase autonomy, self-efficacy, and access to healthcare among Spanish speakers.

Biostatistics Consultation Services Available at CTSC

The Biostatistics, Epidemiology, and Research Design (BERD) Core provides consultation and services, novel tools and methods intended to solve problems, and address barriers to the conduct of clinical and translational research. Services are open to all Health Sciences investigators (staff, students, and faculty) to understand the methodological aspects of their research for planning their projects, including power analysis, sample size, and research design for intermural and extramural grant submissions.

If you have a current pilot study that requires biostatistical support, please schedule appointments as soon as possible.

Are you interested in applying for a pilot study? It is strongly recommended that you make an appointment with one of our biostatisticians prior to your submission. Our expert biostatisticians can help in the initial stages of project development.

Appointments are available; but do fill up quickly. To schedule an appointment, please contact

HSC-CTSCbiostats@salud.unm.edu. Services are offered Monday through Friday.

Please visit our web site: <http://hsc.unm.edu/research/ctsc/biostatistics/index.html>.

Regulatory Knowledge & Support (RKS)

IRB Post Approval Monitoring (PAM) & Audits

The UNMHSC Human Research Protections Office is committed to ensuring that all approved research is conducted in accordance with the IRB approved protocol, federal and state regulations, UNM's institutional policies, and the ethical principles outlined in the Belmont Report. The primary goal of the compliance monitoring is to provide the most current information to investigators through education, training, and monitoring. Upon selection for a PAM, the Principal Investigator will be notified in writing two weeks in advance.

The reason(s) for on-site review may include:

- random selections as part of a regular PAM cycle

- when IRB have cause that a non-compliance has occurred,
- when there is unanticipated problems involving risk to subjects or others
- subject or whistleblower complaints
- requests by an investigator to review their human subject processes

The CTSC Regulatory Knowledge Support (RKS) can assist investigators in preparing for their Post Approval Monitoring visit.

Please contact the CTSC Research Concierge @ HSC-CTSCResearchConcierge@salud.unm.edu for knowledge, assistance and updates regarding any regulatory requirements.

<http://hsc.unm.edu/research/ctsc/regulatory-knowledge-and-support/index.html>

Hub Research Capacity (HRC)

Integrating Special Populations (ISP)

The Health Experiences Research Network, launched in 2014, is a partnership between researchers at University of Wisconsin-Madison, Johns Hopkins University, Oregon Health & Science University, Yale University, University of New Mexico, University of Utah-Salt Lake City, and the Veterans Administration. We're using our combined talents as researchers, innovators, and health care professionals, and our experiences as patients, parents, caregivers, and advocates to bring you real information on the experience of health and illness from a wide range of patients. HERN is committed to implementing the Database of Individual Patient Experiences (DIPEX) methodology in the United States so that each qualitative research study is conducted with rigor and its corresponding public-facing web-based "module" is interpretive, deeply descriptive, and holistic.

Once we have our established themes, they are presented as web-based modules at www.healthexperiencesusa.org. What we learned is organized by categories and topics that help visitors to the website discover what is relevant to them. We take special care to retain the voices of those we interviewed, and include relevant clinical and background information. (source: www.healthexperiencesusa.org)

The UNM CTSC ISP team will be hosting a national web based training for researchers and staff interested in learning about using this methodology on **May 12-14, 2021**. To learn more, please contact Heidi Rishel-Brakey at hrishelbrakey@salud.unm.edu.

Community Health Network (CHN)

The Community Health Network (CHN) continues to make connections with our neighboring communities in rural New Mexico. Cynthia Killough, the program manager, has been attending as many virtual community health council meetings around the state as possible. These meetings provide a wealth of information about health disparities and concerns that are important to rural communities. The meetings

also provide a way for Cynthia to introduce health research at UNM and help break down stigma associated with research in general.



During the pandemic it can be difficult to maintain relationships and network with community members. One strategy Cynthia has used to maintain relationships with community members is by connecting them with resources and others at UNM HSC. The Quay County Community Health Council was promoting suicide prevention and awareness during the month of March and so Cynthia reached out to Dr. Avi Kriechman MD, from the UNM Department of Psychiatry. Dr. Kriechman has nearly 40 years of experience providing behavioral health services to children, adolescents, and families in schools, Tribal, urban, and rural communities and is the Principal Investigator for ASPYR Alliance-building for Suicide Prevention and Youth Resilience. Dr. Kriechman (pictured) generously offered to hold an online community discussion for Quay County about how to enhance safety in their

community & what survivors of suicide loss can do after experiencing said loss.



Step 3. "With a Friend" Coping for Support & Distraction

- Getting Others to Support Your Recovery in Seeking Safety: Notice how **supportive or destructive people** in your life are
- Socialization is for meaning/distraction
- Go to a "healthy" social setting e.g., library, not bar
- Seek support from family, friends, acquaintances
- List more than 1 person as first person might not be available
- List specific people and specific activities
- Role play how person might ask friend to do this activity

During the online event, Dr. Kriechman also introduced the My3 app: a safety planning app that anyone with a smart phone can download free of charge. The event was very well received and Dr. Kriechman received wonderful feedback and many thanks from the Quay County Community Health Council members that attended the event. He also received emails from participants regarding additional resources and referrals for care.

Cynthia was also very grateful for his help addressing the community's health concerns and making it possible for them to take action in addressing suicide. This is a great example of the bidirectionality we hope to continue to foster between communities and UNM HSC.

Network Capacity (NC)

Trial Innovation Network (TIN)

The Trial Innovation Network is a collaborative initiative within the CTSA Program and is composed of three key partners: the CTSA Program Hubs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).

The vision for the Trial Innovation Network is to innovatively address critical roadblocks in clinical research and accelerate the translation of novel interventions into life-saving therapies.

The Trial Innovation Network is a collaborative national network with a focus in three main areas: operational innovation, operational excellence and collaboration. The Trial Innovation Network will leverage the expertise and resources of the CTSA Program. The Trial Innovation Network will feature a single IRB system, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement.

The goal of the Trial Innovation Network is to not only execute trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand and innovate the process of conducting clinical trials.

The University of New Mexico CTSC has been a part of the Trial Innovation Network and as a result has been a participating site in several studies that impact a variety of disease states. This important work has helped connect physicians at the University of New Mexico with the clinical trials specific to their specialty. This effort has encouraged new investigators to become engaged in clinical research. This collaboration is part of the larger mission to move innovated research from the bench, to the bedside, and ultimately out into the communities in which we live.

For more information on the Trial Innovation Network, please contact George Garcia at gemgarcia@salud.unm.edu.

Drug Discovery & Repurposing Core (DDRC)

The DDRC is a Resource for Rapidly Translating Existing Drugs into New Clinical Trials

Do you have ideas about ways to repurpose existing FDA-approved drugs? The CTSC is here to help. Dr. Hakim Djaballah, Module Lead for the Clinical & Translational Science Center Drug Discovery and Repurposing Core (DDRC) collaborates with UNM investigators other CTSCs to improve health outcomes by providing unique resources for rapidly translating existing drugs for use in new clinical trials. DDRC provides access to and operation of state-of-the-art technology in drug rescue, repurposing, and repositioning through innovative tools that support investigators and start-up companies. Additionally, DDRC provides support and guidance in translating pilot projects from preclinical proof-of-principle to clinical proof-of-concept as well as helps to develop first-in-human clinical trials.

For additional information or to become a DDRC member, please visit the DDRC (formerly DR3N) webpage- <https://hsc.unm.edu/research/ctsc/dr3n/index.html>

Clinical Laboratory (T-Laboratory)

The CTSC Translational Laboratory (T-Laboratory) is comprised of 6,000 square feet of wet-lab space, located in the newly renovated CTSC Building. The T-Laboratory offers state-of-the-art equipment and technical assistance with laboratory techniques for UNM HS investigators. The experienced staff of the T-Laboratory provide specialized laboratory support, customized to meet the needs of the investigators in all aspects of research including protocol/assay development, budget preparation, and testing of patient samples for various assays. The T-Laboratory provides sample preparation and technical support for other

non-CTSC resources such as UNM Shared Flow Cytometry and High Throughput Screening Resource, and KUSAIR Small Animal Imaging. In addition, our staff will provide training to UNM HS investigators staff on molecular techniques, clinical techniques, or equipment. There are three options for utilization of CTSC T-Laboratory Services:

- Option A: Full Service Sample Testing
- Option B: Equipment Utilization by Investigator
- Option C: Preparation of Investigator’s Experiments or Train Investigator’s Staff to Perform Assays and Equipment.

Additionally, the CTSC Clinical Laboratory develops and carries out research-related sample analyses for UNM HS investigators, researchers throughout the United States and world, as well as corporate funded research projects.

For questions, please contact HSC-CTSCResearchConcierge@salud.unm.edu.

Funding Opportunities Specific to COVID-19

There are several significant funding opportunities available through the CTSC to address the COVID-19 pandemic. CTSC monitors these opportunities for our HSC faculty on a weekly basis and includes additional information from the NIH COVID-19 funding site for your convenience.

Some of these funding opportunities require an active grant or cooperative agreement. They may also need a Letter of Support from Dr. Larson, the CTSC PI. Please contact Michelle Parra (MMParra@salud.unm.edu) if you are interested in applying for any of the COVID-19 funding opportunities listed below.

Recent Active Funding Opportunities Specific to COVID-19 are listed below:

| Title | Notice Number | Organization(s) | Release Date | RFA/PA/ PAR # | Expiration Date | Activity Code(s) |
|--|-------------------------------|--|--------------|--|-----------------|------------------|
| Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy | NOT-GM-21-021 | NIGMS , SGMRO | Mar 1, 2021 | PA-18-935 | May 1, 2021 | 333 |
| Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs | NOT-TR-21-022 | NCATS | Feb 26, 2021 | PA-20-135 | Aug 17, 2021 | 333 |
| Notice of Special Interest (NOSI): Neurological and Neurocognitive | NOT-AG-21-016 | NIA | Feb 26, 2021 | PA-20-185 PA-20-183 PA-20-184 PA-20-195 | May 8, 2023 | R01, R21, R03 |

| | | | | | | |
|---|-------------------------------|-----------------------|--------------|---|--------------|---------------|
| Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration | | | | PA-20-194 PA-20-196 PA-20-200 | | |
| Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 | NOT-GM-21-019 | NIGMS | Feb 25, 2021 | PA-18-935 | Dec 16, 2021 | 333 |
| Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs for SARS-CoV-2 Surveillance Studies | NOT-GM-21-031 | NIGMS | Feb 18, 2021 | PA-18-935 | Apr 1, 2021 | 333 |
| Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders | NOT-DA-21-019 | NIDA | Feb 10, 2021 | PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146 | Sep 8, 2024 | R01, R03, R21 |
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R03 Clinical Trial Not Allowed) | RFA-AA-21-003 | NIAAA | Feb 5, 2021 | RFA-AA-21-003 | Apr 15, 2021 | R03 |
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R01 Clinical Trial Not Allowed) | RFA-AA-21-002 | NIAAA | Feb 5, 2021 | RFA-AA-21-002 | Apr 15, 2021 | R01 |
| SARS-CoV-2, COVID-19 and Consequences of Alcohol Use (R21 Clinical Trial Not Allowed) | RFA-AA-21-004 | NIAAA | Feb 5, 2021 | RFA-AA-21-004 | Apr 15, 2021 | R21 |
| Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19 | NOT-DA-21-017 | NIDA | Feb 4, 2021 | PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 | Sep 8, 2024 | R01, R02, R03 |

| | | | | | | |
|---|-------------------------------|-----------------------|--------------|---|--------------|---------------|
| Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI) | NOT-AI-21-008 | NIAID | Feb 4, 2021 | PA-20-185 PA-20-195 | Jan 8, 2023 | R01, R21 |
| Notice of Special Interest (NOSI): Urgent Competitive Revisions and Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation | NOT-MD-21-012 | NIMHD | Feb 4, 2021 | PA-20-272 PA-18-935 (Urgent Supplement) | May 4, 2021 | 333 |
| Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders | NOT-DA-21-018 | NIDA | Feb 3, 2021 | PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146 | Sep 8, 2024 | R01, R03, R21 |
| Notice of Special Interest (NOSI): Administrative Supplement Opportunity to Study the Impact of COVID-19 on Global Cancer Prevention and Control | NOT-CA-21-033 | NCI | Feb 3, 2021 | PA-20-272 | Apr 1, 2021 | 333 |
| Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs | NOT-TR-21-017 | NCATS | Feb 3, 2021 | PA-20-272 | Aug 17, 2024 | 333 |
| Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 | NOT-DE-21-001 | NIDCR | Jan 26, 2021 | PA-20-185 PA-20-195 | May 28, 2023 | R01, R21 |

| | | | | | | |
|--|-------------------------------|---|--------------|---|--------------|----------------------------------|
| (COVID-19) | | | | | | |
| Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19) | NOT-AG-21-015 | NIA | Jan 26, 2021 | PA-20-183 PA-20-184 PA-20-185 PA-20-200 PA-20-194 PA-20-196 PA-20-195 PAR-19-374 PAR-19-314 PAR-19-070 PAR-19-071 PAR-20-070 | May 28, 2023 | R01, R03, R21, U19, P01, R21/R33 |
| Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | NOT-DA-21-011 | NIDA | Jan 26, 2021 | PA-20-184 PA-20-183 PA-20-200 PA-20-195 PA-20-194 PA-20-196 PA-20-146 | Sep 8, 2024 | R01, R03, R21 |
| Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed) | RFA-AI-20-078 | NIAID, NIEHS | Jan 12, 2021 | RFA-AI-20-078 | Jun 5, 2021 | U19 |
| Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed) | RFA-AI-20-077 | NIAID, NIEHS | Jan 12, 2021 | RFA-AI-20-077 | Jun 5, 2021 | U01 |
| Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases | NOT-AR-21-012 | NIAMS | Jan 5, 2021 | PA-20-185 PA-20-195 PAR-21-055 PAR-21-054 PAR-21-053 | Nov 19, 2021 | R01, R02 |
| Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research | NOT-MH-21-120 | NIMH | Dec 23, 2020 | PA-20-272 | Jun 2, 2023 | 333 |
| Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities | NOT-MD-21-008 | NIMHD, NIAID, NIAMS, NCI, ORWH, NIMH, NINR, OBSSR, ODP, NHLBI, NIDCR, SGMRO | Dec 17, 2020 | PA-20-183 PA-20-185 | Jan 8, 2022 | R01 |
| Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and | NOT-TR-21-011 | NCATS | Dec 17, 2020 | PAR-18-940 PAR-18-464 PAR-15-304 RFA-TR-14-009 | Jun 2, 2021 | 333 |

| | | | | | | |
|--|-------------------------------|-----------------------|---------------|---|--------------|---------------|
| Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs | | | | | | |
| Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations | NOT-NS-21-037 | NINDS | Mar 15, 2021 | PAR-20-072 | May 6, 2021 | 333 |
| Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects | NOT-AI-21-002 | NIAID | Nov 10, 2020 | PAR-20-072 | Jun 12, 2021 | PO1 |
| Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection | NOT-DA-20-084 | NIDA | Oct 27, 2020 | PA-20-183 PA-20-200 PA-20-195 | Sep 8, 2024 | R01, R03, R21 |
| Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy | NOT-GM-21-032 | NIGMS | Mar 10, 2021 | PAR-20-072 | May 1, 2021 | 333 |
| Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI) | NOT-HL-20-814 | NHLBI | Sept 15, 2020 | PAR-20-183 PAR-20-185 | July 6, 2024 | U01 |
| Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS- | NOT-AI-20-065 | NIAID | Aug 13, 2020 | PAR-18-633 | Sep 1, 2021 | U01 |

| | | | | | | |
|---|-------------------------------|--|--------------|--|----------------|-----|
| CoV-2 | | | | | | |
| Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities | NOT-MD-20-025 | NIMHD, NCI, NIDA, NLM, ODP, OBSSR, NIMH, NIAMS | Aug 13, 2020 | PA-20-185 | May 8, 2023 | R01 |
| Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) | PAR-20-256 | NIAID | Jul 13, 2020 | PAR-20-256 | Jul 8, 2021 | S10 |
| Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) | NOT-AI-20-059 | NIAID | Jul 6, 2020 | PA-20-135 | Jul 2, 2021 | 333 |
| Notice of Special Interest (NOSI): Administrative Supplements and Urgent Competitive Revisions for NIH Grants to Add or Expand Research Focused on Maternal Health, Structural Racism and Discrimination, and COVID-19 | NOT-OD-21-071 | NIH | Mar 5, 2021 | PAR-20-072 PA-18-935 | April 21, 2021 | 333 |
| Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for | NOT-OD-20-129 | NIH, NCI, NHGRI, NCCIH, NINDS, ORIP, NIMHD, NIA, NIDCR, NIAID, NIAMS, NIEHS, NCATS, NIDCD, NICHD, NIDDK, NHLBI | Jun 25, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Jul 13, 2021 | 333 |

| | | | | | | |
|---|-------------------------------|---|--------------|---|--------------|----------------------------|
| Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project | | | | | | |
| Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders | NOT-DC-20-008 | NIDCD | Jun 4, 2020 | PA-18-334 PA-20-185 PA-20-184 PA-20-196 PA-20-195 PA-19-270 PA-19-271 PA-19-273 PA-19-272 | Sep 8, 2022 | R01, R21, R41/R42, R43/R44 |
| Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System | NOT-NS-20-051 | NINDS | Apr 30, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Apr 15, 2021 | 333 |
| Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA | NOT-AA-20-011 | NIAAA | Apr 16, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Apr 16, 2021 | 333 |
| Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences | NOT-OD-20-097 | OBSSR , NCCIH , NCI , NHGRI , NHLBI , NIA , NIAAA , NICHD , NIDDK , NIEHS , NINR , ODP , ORWH | Apr 13, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Apr 1, 2021 | 333 |

| | | | | | | |
|---|-------------------------------|--|--------------|---|--------------|----------|
| Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) | NOT-ES-20-020 | NIEHS | Apr 10, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) RFA-ES-19-011 | May 4, 2021 | 333, R21 |
| Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities | NOT-MD-20-019 | NIMHD, NIA, NIAAA, NIMH, ODP | Apr 9, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | May 1, 2021 | 333 |
| Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus | NOT-TR-20-017 | NCATS | Apr 9, 2020 | PA-20-135 | Jan 26, 2022 | 333 |
| Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus | NOT-MH-20-047 | NIMH, NIA, ODP, NIAAA, NIMHD | Apr 9, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Apr 16, 2021 | 333 |
| Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus | NOT-TR-20-016 | NCATS | Apr 9, 2020 | PA-18-591 | Jan 26, 2022 | 333 |
| Notice of Special Interest (NOSI): NIEHS Support for | NOT-ES-20-015 | NIEHS | Apr 8, 2020 | RFA-ES-19-011 | May 4, 2021 | 333, R21 |

| | | | | | | |
|---|-------------------------------|--|--------------|--|--------------|--------------------------------------|
| Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) | | | | | | |
| Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) | NOT-AG-20-022 | NIA , NIMH | Apr 2, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | May 1, 2021 | 333 |
| RESCINDED - Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) | NOT-AI-20-031 | NIAID | Mar 27, 2020 | Not Applicable-Rescinded | Apr 5, 2021 | R03, R21, 333, R01, R43/R44, R41/R42 |
| Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need | NOT-TR-20-011 | NCATS | Mar 24, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Jul 10, 2021 | 333, U01, R21, U54 |
| Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus | NOT-DA-20-047 | NIDA | Mar 19, 2020 | PA-18-591 (Parent Admin Supplement) PA-18-935 (Urgent Supplement) | Mar 31, 2021 | 333 |
| Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional) | PA-20-135 | NIH , NCATS , NCCIH , NCI , NHGRI , NIA , NIAAA , NIAID , NIAMS , NIBIB , NICHD , NIDCD , NIDDK , NIEHS , NIGMS , NIMH , NIMHD , NINR , NLM , ORWH , | Mar 10, 2020 | PA-20-135 | Sep 8, 2025 | 333 |

| | | | | | | |
|--|-------------------------------|---|--------------|-------------------------------|--------------|-----|
| The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) | RFA-OD-19-029 | OSC ORWH , NCCIH , NHGRI , NHLBI , NIA , NIAAA , NIAID , NIDA , NIDCR , NIEHS , NIMH , NINR | Sep 27, 2019 | RFA-OD-19-029 | Nov 27, 2021 | R01 |
|--|-------------------------------|---|--------------|-------------------------------|--------------|-----|

If you are interested in applying for any of the grants, please email Michelle Parra (MMParra@salud.unm.edu).

For a full listing of COVID-19 through NIH, please access the following site: <https://grants.nih.gov/grants/guide/COVID-Related.cfm>.

Citing the CTSC

When citing the CTSC, please be sure to include our Grant numbers:



Thank you!

HS in the News

For additional Health Sciences news, please visit: <http://hscnews.unm.edu/>

News or corrections?

Please contact [the Newsletter Team](#).

The University Of New Mexico Mailing Address:
 One University of New Mexico
 MSC 08 4635
 Albuquerque, NM 87131